Alherz, F.A.; El-Masry, T.A.; Oriquat, G.A.; Elekhnawy, E.; Al-Shaalan, N.H.; Gaballa, M.M.S.; El Zahaby, E.I.; El-Nagar, M.M.F.
Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. Pharmaceuticals 2024, 17, 1144.
https://doi.org/10.3390/ph17091144
AMA Style
Alherz FA, El-Masry TA, Oriquat GA, Elekhnawy E, Al-Shaalan NH, Gaballa MMS, El Zahaby EI, El-Nagar MMF.
Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. Pharmaceuticals. 2024; 17(9):1144.
https://doi.org/10.3390/ph17091144
Chicago/Turabian Style
Alherz, Fatemah A., Thanaa A. El-Masry, Ghaleb A. Oriquat, Engy Elekhnawy, Nora Hamad Al-Shaalan, Mohamed M. S. Gaballa, Enas I. El Zahaby, and Maysa M. F. El-Nagar.
2024. "Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade" Pharmaceuticals 17, no. 9: 1144.
https://doi.org/10.3390/ph17091144
APA Style
Alherz, F. A., El-Masry, T. A., Oriquat, G. A., Elekhnawy, E., Al-Shaalan, N. H., Gaballa, M. M. S., El Zahaby, E. I., & El-Nagar, M. M. F.
(2024). Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. Pharmaceuticals, 17(9), 1144.
https://doi.org/10.3390/ph17091144
